Compare MCHX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHX | XBIT |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 75.0M |
| IPO Year | 2003 | 2015 |
| Metric | MCHX | XBIT |
|---|---|---|
| Price | $1.72 | $2.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.6K | ★ 27.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,291,000.00 | N/A |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $2.09 |
| 52 Week High | $2.30 | $3.61 |
| Indicator | MCHX | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 66.40 |
| Support Level | $1.59 | $2.15 |
| Resistance Level | $1.74 | $2.69 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 94.92 | 81.25 |
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.